

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bendele et al.

Serial No.: Not Yet Received

Group Art Unit No.: 1646

Filed: July 17, 2001

Examiner: E. O'Hara

For: COMBINATION THERAPY USING A TNF BINDING  
PROTEIN FOR TREATING TNF-MEDIATED  
DISEASES

Docket No.: A-430F

7/B  
M.G.  
4/1/02

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please amend the referenced application as follows:

In the Specification

At page 1, line 3, insert the following paragraph:

This application is a divisional of application Serial No. 09/326,394 filed June 4, 1999, which is a continuation of PCT/US97/22733, filed December 8, 1997, which claims benefit to U.S. Provisional Serial No. 60/032,587, filed December 6, 1996, U.S. Provisional Serial No. 60/036,355, filed January 23, 1997, U.S. Provisional Serial No. 60/039,315, filed February 7, 1997 and U.S. Provisional Serial No. 60/052,023, filed July 9, 1997, all of which are hereby incorporated by reference.

In the Claims

Please cancel claims 2-26 and insert the following new claims:

27. The method of treatment of an acute or chronic inflammatory disease of Claim 1, which comprises administering a TNF binding protein in combination with the prior, concurrent, or post-administration of a COX2 inhibitor.
28. The method of treatment according to claim 27, wherein the COX2 inhibitor is celecoxib.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number: EL360689926US

Date of Deposit: July 17, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Lynne Buchsbaum  
Printed Name

Lynne Buchsbaum  
Signature

6520660  
B-1  
R-1  
B-1

B2  
R-1  
B-1